Discontinued — last reported Q3 '22
Business Segments · Operating income (loss)
Specialty Pharmaceuticals — Operating income (loss)
This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ3 2019
Last reportedQ3 2022
Rolls up toOperating Income
How to read this metric
An increase suggests improved operational efficiency or higher pricing power, whereas a decrease may indicate rising costs, pricing pressure, or declining segment performance.
Detailed definition
This metric measures the profitability of the specialty pharmaceuticals business segment after accounting for direct cos...
Peer comparison
Comparable to segment-level operating income reported by peers in the medical technology and specialty pharma sectors.
Metric ID:
bsx_segment_specialty_pharmaceuticals_operating_income_lossHistorical Data
6 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | |
|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Range$0.00 – $0.00
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's specialty pharmaceuticals — operating income (loss)?
- Boston Scientific (BSX) reported specialty pharmaceuticals — operating income (loss) of $0.00 in Q3 2022.
- What does specialty pharmaceuticals — operating income (loss) mean?
- The profit or loss generated by the specialty pharmaceuticals segment after operating expenses.